Low androgen levels with a corresponding drop in BMPR2 expression could initiate PAH development, as low DHEA-S levels are correlated with worse disease outcome in male PAH patients.166 Further, high androgen-driven Follistatin levels in men might protect from pathogenic signalling by e.g. Activin A in PAH. This evidence concerns the gene FST and pulmonary arterial hypertension.